Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.